Medway Maritime Hospital
Gillingham, Kent, Me7 5NY, United Kingdom
NCT Number: NCT02319096
Pelvic floor muscle training (PFMT) is the first line therapy recommended by NICE for the treatment of SUI. Due to poor motivation and compliance only 15-20% of women comply with the regimen. Whole body vibration (WBV) exercise has been developed as a new modality in the field of physiotherapy. The Galileo machine is a unique device for applying whole-body vibration. The investigators are currently using this therapy as an alternative to traditional pelvic floor muscle therapy. The investigators aim to audit the investigators treatment of whole body vibration.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Not applicable
Gillingham, Kent, Me7 5NY, United Kingdom
Pelvic floor muscle training (PFMT) is the first line therapy recommended by NICE for the treatment of SUI. It was first described by Arnold Kegel almost 60 years ago. PFMT exercises help the patient strengthen the muscles of the pelvic floor by the repeated high-intensity, rapid pelvic muscle contractions of both slow and fast twitch muscle fibres. The training of these muscles is difficult particularly when women have trouble in the perception of their PFM. This results in poor motivation and compliance with a Cochrane review suggesting that only 15-20% of women comply with the regimen.
Whole body vibration (WBV) exercise has been developed as a new modality in the field of physiotherapy. Whole body vibration (WBW) has a positive effect on muscle strength and rate of force. Stochastic WBV causes up to 12 muscle contractions per second which cannot be achieved by routine PFM exercise with supervision of a physiotherapist. The Galileo machine is a unique device for applying whole-body vibration. The investigators aim to audit their treatment of whole body vibration. This would be done using the patient global impression of improvement scale (PGI-I) and routine quality of life and symptoms questionnaires (International Consultation on Incontinence Female lower Urinary Tract Symptoms Questionnaire -ICIQ-FLUTS and Pelvic Floor Distress Inventory - PFDI) to be completed by the patient at initial appointment and 12 weeks after treatment and pelvic floor muscle assessment carried out at initial appointment and at 12 weeks. Patients will also have a qualitative interview with the Urogynaecology team to assess if therapy was found to be suitable and acceptable to patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Whole body vibration therapy using the Galileo machine as therapy for pelvic floor muscle training
Time frame: 12 weeks
Patients will be asked answer the PGI-I questionnaire after a full 12 week course of therapy
Time frame: 12 weeks
Patients will be asked to answer the ICIQ-FLUTS to assess symptom improvement after a full 12 week course of therapy
Time frame: 12 weeks
Patients will be asked to answer the PFDI-I to assess any improvement in quality of life after a full 12 weeks
Time frame: 12 weeks
A qualitative interview will be conducted with the urogynaecology team to assess if patients found the new therapy suitable and acceptable.
Time frame: 12 weeks
Pelvic muscle contraction will be measured at Week 0 and Week 12 using a pelvic perineometer to assess any improvement in pelvic muscle strength
Medway NHS Foundation Trust
Other
Whole Body Vibration Plate Therapy and Pelvic Floor Muscle Strength in Females With Stress Urinary Incontinence
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04817839
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
New Haven, Connecticut, United States
View Trial DetailsNCT06508944
Bladder, Overactive, Female Genitourinary Disease
Ratchathewi, Bangkok, Thailand
View Trial DetailsNCT03672461
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Palo Alto, California, United States
View Trial DetailsNCT05961241
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Haifa, Israel
View Trial Details